Dabrafenib - CAS# 1195765-45-7 size:2mg solid tight-binding kinetics) of LpxC from

tight-binding kinetics) of LpxC from Rhizobium leguminosarum (Ki=340 nM)

) attenuates DMBA-induced mammary tumorigenesis in mice

LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2

Characterization of the cellular and antitumor effects of MPI-0479605

1-1 µM final concentration in vitro and in cellular assays

Dabrafenib - CAS# 1195765-45-7 size:2mg solid tight-binding kinetics) of LpxC fromDabrafenib, CAS No. 1195765 45 7, also known as GSK2118436 , is an orally bioavailable inhibitor of B raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B raf belongs to the the raf mil family of serine threonine protein kinases and plays a role in regulating the MAP kinase ERKs signaling